Building Your Care Team: Coordinating Bone Health and Disease Control
At a Glance
Glucocorticoid-induced osteoporosis is safest to manage with a coordinated team: the clinician treating the underlying disease, a bone-health provider, and primary care. They should share plans for steroid tapering, fracture-risk monitoring, lab checks, and adrenal safety.
Protecting your bones while managing a serious inflammatory condition requires a “team-based” approach. Because steroids affect both your underlying disease and your skeleton, no single doctor can manage your health in a vacuum. Building a care team that communicates effectively ensures that your bones are protected while your disease is controlled [1][2].
Clarifying Your Care Team Roles
While your primary care provider (PCP) is your home base, GIOP requires establishing who handles specific responsibilities. Your care team may include Rheumatologists, Endocrinologists, Pulmonologists, Gastroenterologists, or PCPs [3][4].
- The Disease Manager & Prescriber: The clinician managing the condition that requires steroids. They are responsible for keeping your inflammation low, adjusting the steroid dose, and directing the taper.
- The Bone Health Manager: This clinician (PCP, Rheumatologist, or other trained provider) orders DXA scans, prescribes osteoporosis medications, and manages follow-up. An endocrinologist is not required for everyone, but a referral is useful for diagnostic uncertainty, complex medication choices, or severe disease [5][6].
- The Foundational Care Coordinator: Often your PCP, this clinician monitors your overall health, including Vitamin D, calcium levels, kidney function, and fall risk [7][8].
Coordinating the ‘Taper’ and Adrenal Safety
One of the most important discussions your team will have is when and how to “taper” (gradually reduce) your steroids.
- Disease Control: Tapering too fast can cause your underlying condition to flare up [9].
- Adrenal Safety: If you have been on steroids for more than 3–4 weeks at a sufficiently high dose, your body may have temporarily stopped making its own natural cortisol. While not everyone is suppressed at this threshold, it is a common risk marker [6][10]. Never stop or change systemic steroids on your own without the prescribing clinician.
- Sick-Day/Emergency Guidance: Ask for a written sick-day/stress-dose plan. You may need a medical alert card. Seek urgent care if you experience symptoms like persistent vomiting, severe weakness, fainting, confusion, or low blood pressure during a taper or illness.
Preparing for Your First Bone Consultation
Your first visit with a bone specialist is a deep dive into your medical history. To get an accurate fracture-risk score, you should bring the following “artifacts” [11][12]:
- The Steroid Log: A list of your current daily dose, how long you’ve been taking it, and any “pulses” or high-dose bursts you’ve had in the last year [12].
- Imaging Records: Hard copies or digital access to previous DXA scans and any X-rays of your back or hips. Serial DXA scans can be interpreted using the “least significant change” threshold, preferably when done on the same machine [13][14].
- Comprehensive Medication List: Include not just your steroids, but also drugs like proton-pump inhibitors (for reflux) or certain antidepressants, as these can also affect bones [12][15].
- Recent Lab Results: Specifically, your eGFR/Creatinine (kidney function), Calcium, and 25-hydroxyvitamin D levels. Additional labs may be required based on your clinical evaluation to ensure medications are safe [12][16].
Vetting Your Specialist
GIOP is different from standard age-related osteoporosis. When meeting a new specialist, it is important to confirm they follow current guidelines, which emphasize using tools like FRAX (adjusted for steroid dose) and Vertebral Fracture Assessment (VFA) when clinically indicated to look for silent damage [13][12].
Common questions in this guide
Who should manage my glucocorticoid-induced osteoporosis?
What should I bring to my first GIOP bone appointment?
Can I stop steroids suddenly if I am worried about my bones?
When should I see an endocrinologist for GIOP?
How is fracture risk monitored in glucocorticoid-induced osteoporosis?
What symptoms during a steroid taper require urgent care?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How much of your practice is dedicated to managing glucocorticoid-induced osteoporosis (GIOP) compared to postmenopausal osteoporosis?
- 2.Which of you—the specialist managing my inflammation or the one managing my bone health—will be responsible for initiating my steroid taper?
- 3.How will you communicate my fracture risk and treatment plan to my primary care doctor and the physician who originally prescribed my steroids?
- 4.What is your specific protocol for monitoring my bone health if my steroid dose increases or if we decide to stop my steroids entirely?
- 5.If I experience symptoms of adrenal insufficiency during a taper, like extreme fatigue or vomiting, which member of the team should I contact first?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis.
Abdullah H, Koller G, Zuna I, et al.
Archives of osteoporosis 2021; (16(1)):108 doi:10.1007/s11657-021-00979-6.
PMID: 34347188 - 2
Glucocorticoid prescribing in neurology.
Jones AP, Debono M, Walsh J, et al.
Practical neurology 2024; (24(4)):289-295 doi:10.1136/pn-2023-003855.
PMID: 38553045 - 3
Glucocorticoid-induced osteoporosis.
Briot K, Roux C
RMD open 2015; (1(1)):e000014 doi:10.1136/rmdopen-2014-000014.
PMID: 26509049 - 4
Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database.
Trijau S, de Lamotte G, Pradel V, et al.
RMD open 2016; (2(2)):e000249 doi:10.1136/rmdopen-2016-000249.
PMID: 27486526 - 5
Weaning patients off long-term prednisolone: a survey of physicians' practice in the UK and Southeast Asia.
Lazarus K, Eng PC, Narula K, et al.
BMJ open 2025; (15(12)):e107269 doi:10.1136/bmjopen-2025-107269.
PMID: 41469042 - 6
Practical guidance for stopping glucocorticoids.
Khalili F, Burt MG
Australian prescriber 2025; (48(4)):116-121 doi:10.18773/austprescr.2025.037.
PMID: 40861402 - 7
Nationwide prevalence of glucocorticoid prescriptions over 17 years and osteoporosis prevention among long-term users.
Bjornsdottir HH, Einarsson ÓB, Gröndal G, Gudbjornsson B
SAGE open medicine 2024; (12()):20503121241235056 doi:10.1177/20503121241235056.
PMID: 38516640 - 8
Evaluation of Steroid-Induced Osteoporosis Prevention Using Tracing Reports in Collaboration between Hospitals and Community Pharmacists.
Ishihara N, Yamashita S, Seiki S, et al.
Pharmacy (Basel, Switzerland) 2024; (12(3)) doi:10.3390/pharmacy12030080.
PMID: 38804472 - 9
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR, Buttgereit F, Bernasconi C, et al.
Lancet (London, England) 2020; (396(10246)):267-276 doi:10.1016/S0140-6736(20)30636-X.
PMID: 32711802 - 10
Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review.
Joseph RM, Hunter AL, Ray DW, Dixon WG
Seminars in arthritis and rheumatism 2016; (46(1)):133-41.
PMID: 27105755 - 11
Drug-Induced Osteoporosis.
Gasser RW, Kocijan R, Zendeli A, Resch H
Journal of clinical medicine 2026; (15(3)) doi:10.3390/jcm15030993.
PMID: 41682673 - 12
Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society.
Paccou J, Yavropoulou MP, Naciu AM, et al.
European journal of endocrinology 2024; (191(6)):G1-G17 doi:10.1093/ejendo/lvae146.
PMID: 39556468 - 13
2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Humphrey MB, Russell L, Danila MI, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(12)):2088-2102 doi:10.1002/art.42646.
PMID: 37845798 - 14
Pan Arab Osteoporosis Society Guidelines for Osteoporosis Management.
Jassim NA, Adib G, Abdul Rahman YA, et al.
Mediterranean journal of rheumatology 2017; (28(1)):27-32 doi:10.31138/mjr.28.1.27.
PMID: 32185251 - 15
Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases.
Buttgereit F, Palmowski A, Bond M, et al.
Nature reviews. Rheumatology 2024; (20(7)):417-431 doi:10.1038/s41584-024-01120-w.
PMID: 38831028 - 16
[German Society of Rheumatology Recommendations for the management of glucocorticoid-induced Osteoporosis. German version].
Leipe J, Holle JU, Weseloh C, et al.
Zeitschrift fur Rheumatologie 2021; (80(7)):670-687 doi:10.1007/s00393-021-01028-w.
PMID: 34357436
This page is for informational purposes only and does not constitute medical advice. Do not start, stop, or change steroids or osteoporosis treatment without guidance from your prescribing clinician and care team.
Get notified when new evidence is published on glucocorticoid-induced osteoporosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.